Gabriela S. Hobbs, MD

Gabriela S. Hobbs, MD, discusses how to distinguish proliferative from cytopenic myelofibrosis and the role of risk stratification.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Gabriela Hobbs, MD, discusses the role of molecular testing to determine resistance in chronic myeloid leukemia.

Gabriela Hobbs, MD, shares advice on how to choose the appropriate second-line treatment option for patients with chronic lymphocytic leukemia who are resistant to TKIs.

Gaby Hobbs, MD, discusses managing ponatinib-associated toxicities in chronic myeloid leukemia.

Gabriela S. Hobbs, MD, clinical director, Leukemia Service, assistant in medicine, Massachusetts General Hospital, discusses the treatment landscape of chronic myeloid leukemia.

Gabriela S. Hobbs, MD, clinical director, Leukemia Service, assistant in medicine, Massachusetts General Hospital, discusses the updated NCCN guidelines in chronic myeloid leukemia (CML).